A human monoclonal antibody potently pan-neutralizes SARS-CoV-2 VOCs by targeting RBD invariant sites

Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and treat COVID-19. However, SARS-CoV-2 variants of concern (VOCs) profoundly reduced the efficacies of most of mAbs and vaccines approved for clinical use. Herein, we demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and VOCs, including B.1.617.2 (delta) variant, in vitro and in vivo. Cryo-electron microscopy (cryo-EM) revealed that 35B5 neutralizes SARS-CoV-2 by targeting a unique epitope that avoids the prevailing mutation sites on RBD identified in circulating VOCs, providing the molecular basis for its pan-neutralizing efficacy. The 35B5-binding epitope could also be exploited for the rational design of a universal SARS-CoV-2 vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (7348)
- Bioengineering (5324)
- Bioinformatics (20266)
- Biophysics (10019)
- Cancer Biology (7744)
- Cell Biology (11305)
- Clinical Trials (138)
- Developmental Biology (6437)
- Ecology (9953)
- Epidemiology (2065)
- Evolutionary Biology (13325)
- Genetics (9361)
- Genomics (12586)
- Immunology (7702)
- Microbiology (19024)
- Molecular Biology (7443)
- Neuroscience (41041)
- Paleontology (300)
- Pathology (1229)
- Pharmacology and Toxicology (2138)
- Physiology (3161)
- Plant Biology (6861)
- Synthetic Biology (1896)
- Systems Biology (5313)
- Zoology (1089)